{"entity":{"type":"insider","cik":"0001666306","url":"/insider/0001666306","json_url":"/insider/0001666306.json","name":"ARCH Venture Fund IX, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":10,"n_filings":6,"first":"2019-07-02","last":"2026-07-06","span_basis":"filed_date"},"name_variants":[{"name":"ARCH Venture Fund IX, L.P.","source":"filing","n_filings":6,"first_seen":"2019-07-02","last_seen":"2026-07-06"}],"transactions":[{"id":5892202,"accession":"0001012975-26-000621","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001012975-26-000621","line_url":"/filing/0001012975-26-000621#line-2","is_derivative":false,"issuer_cik":"0001666306","issuer_name":"Boundless Bio, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001666306","owner_cik":null,"owner_name":"ARCH Venture Fund X Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners X, LLC; ARCH Venture Partners IX, LLC; ARCH Venture Partners X Overage, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16000.0,"shares_display":"16,000","price_per_share":2.49,"price_display":"2.49","price_state":"stated","total_value":39840.0,"total_display":"39,840.00","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-01","filed_date":"2026-07-06","scope":"insider"},{"id":5805420,"accession":"0001012975-26-000235","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-26-000235","line_url":"/filing/0001012975-26-000235#line-1","is_derivative":false,"issuer_cik":"0001666306","issuer_name":"Lyell Immunopharma, Inc.","issuer_ticker":"LYEL","issuer_name_source":null,"issuer_url":"/issuer/0001666306","owner_cik":null,"owner_name":"ARCH Venture Fund IX, L.P.; ARCH Venture Fund IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":488090.0,"shares_display":"488,090","price_per_share":25.61,"price_display":"25.61","price_state":"stated","total_value":12499984.9,"total_display":"12,499,984.90","shares_owned_after":1426528.0,"shares_owned_after_display":"1,426,528","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-06","filed_date":"2026-03-09","scope":"insider"},{"id":3151686,"accession":"0000950170-24-041841","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-24-041841","line_url":"/filing/0000950170-24-041841#line-5","is_derivative":false,"issuer_cik":"0001666306","issuer_name":"Boundless Bio, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001666306","owner_cik":null,"owner_name":"ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Fund X Overage, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":133333.0,"shares_display":"133,333","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":2133328.0,"total_display":"2,133,328.00","shares_owned_after":1181766.0,"shares_owned_after_display":"1,181,766","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-02","filed_date":"2024-04-04","scope":"insider"},{"id":3151684,"accession":"0000950170-24-041841","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-24-041841","line_url":"/filing/0000950170-24-041841#line-4","is_derivative":false,"issuer_cik":"0001666306","issuer_name":"Boundless Bio, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001666306","owner_cik":null,"owner_name":"ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Fund X Overage, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":66667.0,"shares_display":"66,667","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":1066672.0,"total_display":"1,066,672.00","shares_owned_after":683759.0,"shares_owned_after_display":"683,759","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-02","filed_date":"2024-04-04","scope":"insider"},{"id":2997071,"accession":"0001062993-24-002840","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-24-002840","line_url":"/filing/0001062993-24-002840#line-3","is_derivative":false,"issuer_cik":"0001666306","issuer_name":"Sana Biotechnology, Inc.","issuer_ticker":"SANA","issuer_name_source":null,"issuer_url":"/issuer/0001666306","owner_cik":null,"owner_name":"ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC; ARCH Venture Partners X, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Fund IX Overage, L.P.; ARCH Venture Partners X, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":727272.0,"shares_display":"727,272","price_per_share":5.5,"price_display":"5.50","price_state":"stated","total_value":3999996.0,"total_display":"3,999,996.00","shares_owned_after":12446022.0,"shares_owned_after_display":"12,446,022","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-08","filed_date":"2024-02-12","scope":"insider"},{"id":2997068,"accession":"0001062993-24-002840","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-24-002840","line_url":"/filing/0001062993-24-002840#line-2","is_derivative":false,"issuer_cik":"0001666306","issuer_name":"Sana Biotechnology, Inc.","issuer_ticker":"SANA","issuer_name_source":null,"issuer_url":"/issuer/0001666306","owner_cik":null,"owner_name":"ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC; ARCH Venture Partners X, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Fund IX Overage, L.P.; ARCH Venture Partners X, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":727272.0,"shares_display":"727,272","price_per_share":5.5,"price_display":"5.50","price_state":"stated","total_value":3999996.0,"total_display":"3,999,996.00","shares_owned_after":12446022.0,"shares_owned_after_display":"12,446,022","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-08","filed_date":"2024-02-12","scope":"insider"},{"id":2997064,"accession":"0001062993-24-002840","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-24-002840","line_url":"/filing/0001062993-24-002840#line-1","is_derivative":false,"issuer_cik":"0001666306","issuer_name":"Sana Biotechnology, Inc.","issuer_ticker":"SANA","issuer_name_source":null,"issuer_url":"/issuer/0001666306","owner_cik":null,"owner_name":"ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC; ARCH Venture Partners X, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Fund IX Overage, L.P.; ARCH Venture Partners X, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":363637.0,"shares_display":"363,637","price_per_share":5.5,"price_display":"5.50","price_state":"stated","total_value":2000003.5,"total_display":"2,000,003.50","shares_owned_after":10667387.0,"shares_owned_after_display":"10,667,387","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-08","filed_date":"2024-02-12","scope":"insider"},{"id":8601297,"accession":"0001209191-19-053664","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-053664","line_url":"/filing/0001209191-19-053664#line-3","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Vir Biotechnology, Inc.","issuer_ticker":"VIR","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners IX Overage, L.P.; ARCH Venture Fund IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Fund IX, L.P.; BYBEE CLINTON; ARCH Venture Partners IX, LLC; CRANDELL KEITH","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000000.0,"shares_display":"1,000,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":20000000.0,"total_display":"20,000,000.00","shares_owned_after":1000000.0,"shares_owned_after_display":"1,000,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-10-16","filed_date":"2019-10-18","scope":"insider"},{"id":7830899,"accession":"0000899243-19-018905","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-19-018905","line_url":"/filing/0000899243-19-018905#line-6","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Fund IX, L.P.; BYBEE CLINTON; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX Overage, L.P.; CRANDELL KEITH; ARCH Venture Partners IX, LLC; ARCH Venture Fund IX Overage, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":1600000.0,"total_display":"1,600,000.00","shares_owned_after":100000.0,"shares_owned_after_display":"100,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-07-02","filed_date":"2019-07-02","scope":"insider"},{"id":7830896,"accession":"0000899243-19-018905","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-19-018905","line_url":"/filing/0000899243-19-018905#line-5","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Fund IX, L.P.; BYBEE CLINTON; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX Overage, L.P.; CRANDELL KEITH; ARCH Venture Partners IX, LLC; ARCH Venture Fund IX Overage, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":1600000.0,"total_display":"1,600,000.00","shares_owned_after":100000.0,"shares_owned_after_display":"100,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-07-02","filed_date":"2019-07-02","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001782303","name":"Boundless Bio, Inc.","url":"/issuer/0001782303","role":"Ten percent owner","n_filings":2,"first_seen":"2024-04-04","last_seen":"2026-07-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001806952","name":"Lyell Immunopharma, Inc.","url":"/issuer/0001806952","role":"Ten percent owner","n_filings":1,"first_seen":"2026-03-09","last_seen":"2026-03-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001770121","name":"Sana Biotechnology, Inc.","url":"/issuer/0001770121","role":"Ten percent owner","n_filings":1,"first_seen":"2024-02-12","last_seen":"2024-02-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001706431","name":"Vir Biotechnology, Inc.","url":"/issuer/0001706431","role":"Ten percent owner","n_filings":1,"first_seen":"2019-10-18","last_seen":"2019-10-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001771917","name":"Karuna Therapeutics, Inc.","url":"/issuer/0001771917","role":"Ten percent owner","n_filings":1,"first_seen":"2019-07-02","last_seen":"2019-07-02"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001666306","retrieved_at":"2026-08-21T02:33:49+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-19","last_ingest":"2026-08-20T05:22:56.381658+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}